UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Not all low-cost index funds support drip, so compare available options and setup steps to automate reinvestment and maximize growth.
26,805 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
As demand for nickel, copper, cobalt, and manganese grows, TMC faces a pivotal path. This article breaks down two maj...
As AI reshapes the market, one trillion-dollar stock rises above the rest in analysts’ eyes. Learn why it stands out,...
Microsoft stock has pulled back in a surprising turn for a tech giant. This article unpacks the reasons behind the dr...
AI infrastructure has reshaped markets, but not every stock fits every investor. This guide explains what CoreWeave d...
Nvidia just delivered another earnings beat and a bold $80 billion buyback. As AI infrastructure spending accelerates...
When a CEO sells a sizable stake, investors ask: what does it mean for the stock? This piece unpacks Universal Techni...
When rhythm pharma (rytm) releases earnings, investors get a window into revenue growth, cash health, and pipeline pr...
OpenAI’s growing power needs are drawing attention to a little-known Michigan utility tied to a major data-center dea...
Hynix’s move onto the Nasdaq marks a watershed moment for foreign listings in the U.S. tech space. This article break...
Hovnanian Enterprises reports a profit for Q1 2026 as it shifts focus to higher-margin homes. The move aims to lift m...
Investors cheered a decisive move higher as Okta unveiled AI-powered growth opportunities. The stock touched a new 52...